Interestingly, recent studies have suggested that comorbidities such as hypercholesterolemia, prediabetes, and metabolic syndrome may impair cardioprotective interventions, including insulin treatment and ischemic pre- and postconditioning [43]. The gene discussed is INS; the disease is Hypercholesterolemia.